Proteolytic Antibody HIVcides
蛋白水解抗体杀艾滋病剂
基本信息
- 批准号:7286844
- 负责人:
- 金额:$ 20.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-15 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody-Producing CellsArchitectureB-LymphocytesBindingCD4 Positive T LymphocytesCatalytic AntibodiesCell FractionationCell LineClassCoitusConditionDevelopmentDrug FormulationsEnvironmentExcipientsHIVHIV Envelope Protein gp120HIV SeropositivityImmuneImmunizationImmunoglobulin AImmunoglobulin GIn VitroInfectionLocal MicrobicidesLupusLymphocyteMacacaModelingMolecularPatientsPhasePropertyProphylactic treatmentRateReactionRiskSalivarySerumSexual TransmissionSimulateSiteSpecificitySuperantigensVaginaVariantanalogbasecatalystcostdesireenv Gene Productsimprovedin vivomicrobicidenovelpandemic diseasepeptide analogpolyclonal antibodyresistance factors
项目摘要
DESCRIPTION (provided by applicant): A specific, irreversible and cost-effective topical microbicide for HIV prophylaxis will help slow sexual transmission of the pandemic. Here, we propose the development of catalytic antibodies capable of degrading the HIV envelope protein gp120 as candidate HIVcides. The promising features of the antibodies are the permanent destruction of the envelope protein, reuse of a single catalyst molecule to degrade thousands of gp120 molecules and the recognition of a conserved gp120 region, the superantigen region, permitting neutralization of diverse HIV strains. Polyclonal antibody studies from uninfected and HIV infected subjects indicated that high level proteolytic and HIV neutralizing activities is a noteworthy property of IgA class antibodies. In the R21 project phase, characterization of our existing antibodies and their single chain Fv (scFv), IgA and IgG variants is proposed. The existing antibodies were obtained as IgGs by immunization with an electrophilic gp120 analog that induces antibodies with enhanced nucleophilic reactivity, a prerequisite for the catalytic reaction. Using an electrophilic probe to the gp120 superantigen site, additional proteolytic antibodies were obtained as scFv constructs cloned from the immune repertoire of lupus patients, who tend to produce antibodies with proteolytic activity directed to the gp120 superantigen site. The antibodies will be characterized with respect to HIV degrading efficiency; specificity, potency and breadth of HIV neutralization; and the ability to perform these functions in the vaginal milieu. To isolate novel, improved antibodies, we will screen the proteolytic and HIV neutralizing activity of salivary and serum IgAs from HIV-negative and HIV-positive subjects in the R21 project phase. In the R33 phase, monoclonal IgAs with the desired properties will be cloned from lymphocytes by cell-fractionation based on covalent binding of an electrophilic gp120 peptide analog, a property associated with proteolytic antibody-producing cells. Proof-of-principle for in vivo antibody efficacy will be obtained in the R33 phase using the SHIV-macaque model of infection. The Abs will also be examined for activity in vitro as microbicide excipient formulations under conditions simulating the vaginal environment following sexual intercourse. These studies may identify proteolytic antibodies suitable for further development as a topical HIVcide.
描述(由申请人提供):一种用于艾滋病毒预防的特异性、不可逆和具有成本效益的局部杀微生物剂将有助于减缓该流行病的性传播。在这里,我们建议开发能够降解HIV包膜蛋白gp 120的催化抗体作为候选HIV杀剂。这些抗体的有前途的特点是包膜蛋白的永久性破坏,重复使用一个单一的催化剂分子降解数千个gp 120分子,并识别一个保守的gp 120区域,超抗原区域,允许中和不同的HIV毒株。未感染和HIV感染受试者的多克隆抗体研究表明,高水平的蛋白水解和HIV中和活性是伊加类抗体的一个值得注意的特性。在R21项目阶段,提出了我们现有抗体及其单链Fv(scFv)、伊加和IgG变体的表征。现有的抗体通过用亲电子gp 120类似物免疫获得IgG,所述亲电子gp 120类似物诱导具有增强的亲核反应性的抗体,这是催化反应的先决条件。使用亲电子探针的gp 120超抗原位点,获得额外的蛋白水解抗体的scFv构建体克隆从狼疮患者的免疫库,谁往往产生抗体的蛋白水解活性针对gp 120超抗原位点。抗体将在HIV降解效率; HIV中和的特异性、效力和广度;以及在阴道环境中执行这些功能的能力方面进行表征。为了分离新型改良抗体,我们将在R21项目阶段筛选来自HIV阴性和HIV阳性受试者的唾液和血清IgA的蛋白水解和HIV中和活性。在R33阶段,将通过基于亲电子gp 120肽类似物的共价结合的细胞分级分离从淋巴细胞克隆具有所需性质的单克隆IgA,所述亲电子gp 120肽类似物的共价结合是与蛋白水解抗体产生细胞相关的性质。将在R33阶段使用SHIV-猕猴感染模型获得体内抗体效力的原理证明。还将在模拟性交后阴道环境的条件下检查Ab作为杀微生物剂赋形剂制剂的体外活性。这些研究可能会确定蛋白水解抗体适合进一步发展为一个局部HIV杀。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sudhir Paul其他文献
Sudhir Paul的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sudhir Paul', 18)}}的其他基金
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
- 批准号:
8728715 - 财政年份:2010
- 资助金额:
$ 20.66万 - 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
- 批准号:
7984646 - 财政年份:2010
- 资助金额:
$ 20.66万 - 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
- 批准号:
8320914 - 财政年份:2010
- 资助金额:
$ 20.66万 - 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
- 批准号:
8527652 - 财政年份:2010
- 资助金额:
$ 20.66万 - 项目类别:
Efficacious and safe antibody catalyzed amyloid beta clearance
有效且安全的抗体催化β淀粉样蛋白清除
- 批准号:
8144329 - 财政年份:2010
- 资助金额:
$ 20.66万 - 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
- 批准号:
7341060 - 财政年份:2007
- 资助金额:
$ 20.66万 - 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
- 批准号:
7577404 - 财政年份:2007
- 资助金额:
$ 20.66万 - 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
- 批准号:
7230575 - 财政年份:2007
- 资助金额:
$ 20.66万 - 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
- 批准号:
7759599 - 财政年份:2007
- 资助金额:
$ 20.66万 - 项目类别:
Nucleophilic Antibodies: Characterization and Induction
亲核抗体:表征和诱导
- 批准号:
8015976 - 财政年份:2007
- 资助金额:
$ 20.66万 - 项目类别:
相似海外基金
The role of IgD antibody-producing cells in the generation of allergen-specific IgE in type I allergy
IgD 抗体生成细胞在 I 型过敏中过敏原特异性 IgE 生成中的作用
- 批准号:
20K07537 - 财政年份:2020
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Modulating immunological memory of antibody-producing cells
调节抗体产生细胞的免疫记忆
- 批准号:
17K19539 - 财政年份:2017
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Detection of specific antibody-producing cells with the enzyme-labeled antigen method in paraffin sections
石蜡切片中酶标抗原法检测特异性抗体产生细胞
- 批准号:
15K19063 - 财政年份:2015
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Application of an enzyme-labeled antigen method for visualizing specific antibody-producing cells in nasal polyp tissue
应用酶标抗原法可视化鼻息肉组织中特异性抗体产生细胞
- 批准号:
25870873 - 财政年份:2013
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Deciphering the antibody-independent functions of antibody-producing cells in autoimmune diseases (18)
破译自身免疫性疾病中抗体产生细胞的独立于抗体的功能 (18)
- 批准号:
243115857 - 财政年份:2013
- 资助金额:
$ 20.66万 - 项目类别:
CRC/Transregios
Experimental study on induction of anti-virus antibody producing cells into the brain
抗病毒抗体产生细胞诱导进入脑内的实验研究
- 批准号:
23780306 - 财政年份:2011
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
How genes are regulated when antibody producing cells b ecome scavenger cells
当抗体产生细胞变成清道夫细胞时,基因如何受到调节
- 批准号:
nhmrc : 900126 - 财政年份:1990
- 资助金额:
$ 20.66万 - 项目类别:
NHMRC Project Grants
Specific elimination of anti-DNA antibody-producing cells in systemic lupus erythematosus.
特异性消除系统性红斑狼疮中产生抗 DNA 抗体的细胞。
- 批准号:
59870026 - 财政年份:1984
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research
PURIFICATION AND SEPARATION OF ANTIBODY -PRODUCING CELLS
抗体产生细胞的纯化和分离
- 批准号:
7243101 - 财政年份:1972
- 资助金额:
$ 20.66万 - 项目类别: